Liu Shu, Zhao Yanru, Li Miaojing, Xi Jieying, Shi Bingyin, Zhu Huachao
Department of Endocrinology.
Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China.
Medicine (Baltimore). 2019 Jan;98(3):e14180. doi: 10.1097/MD.0000000000014180.
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy. However, the simultaneous occurrence of PTC and Hodgkin Lymphoma (HL) was rarely reported.
We present a case of simultaneous BRAF-positive PTC and HL in a 17-year-old female.
She was referred to our clinic with a painless lump in her left neck. A highly suspicious thyroid nodule and multiple enlarged lymph nodes in the neck were found by ultrasonography examination. The suspicious nodule was diagnosed as PTC by fine needle aspiration cytology.
A total thyroidectomy with bilateral lymph node dissection was performed and the microscopic examination revealed a 2-cm PTC with BRAF mutation and HL (mixed cellularity) in the bilateral lymph nodes. PTC was postoperatively considered as T1bN0M0. Levothyroxine (125 μg/d) was administered to the patient for thyrotropin suppression therapy. Then the patient was referred to the Department of Hematology to receive 4 cycles of ABVD followed by 30 Gy involved-site radiotherapy and radioactive iodine (RAI) therapy for thyroid cancer.
After two cycles of ABVD, multiple enlarged lymph nodes showed a significant response to the chemotherapy in the patient.
Simultaneous HL and BRAF-positive PTC is extremely rare. Biopsy of the suspicious lymph nodes should be performed to confirm malignancy metastasizing from PTC or other lesions. Similarly, in HL patients with suspicious thyroid nodule, ultrasound-guided fine needle aspiration of thyroid nodule should be performed to exclude thyroid malignancy.
甲状腺乳头状癌(PTC)是最常见的内分泌恶性肿瘤。然而,PTC与霍奇金淋巴瘤(HL)同时发生的情况鲜有报道。
我们报告一例17岁女性同时患有BRAF阳性PTC和HL的病例。
她因左颈部无痛性肿块被转诊至我们诊所。超声检查发现一个高度可疑的甲状腺结节和颈部多个肿大淋巴结。通过细针穿刺细胞学检查,可疑结节被诊断为PTC。
进行了全甲状腺切除术及双侧淋巴结清扫术,显微镜检查显示为一个2厘米的BRAF突变型PTC,双侧淋巴结存在HL(混合细胞型)。术后PTC被判定为T1bN0M0。给予患者左甲状腺素(125μg/d)进行促甲状腺激素抑制治疗。随后患者被转诊至血液科接受4个周期的ABVD化疗,接着进行30Gy的受累部位放疗及甲状腺癌放射性碘(RAI)治疗。
两个周期的ABVD化疗后,患者颈部多个肿大淋巴结对化疗有显著反应。
HL与BRAF阳性PTC同时发生极为罕见。应对可疑淋巴结进行活检以确认是否为PTC转移或其他病变导致的恶性肿瘤。同样,对于有可疑甲状腺结节的HL患者,应进行超声引导下甲状腺结节细针穿刺以排除甲状腺恶性肿瘤。